BASEL, Switzerland, July 21 (Reuters) - Swiss drugmaker Roche Genentech deal
and that there would be no need for a capital increase.
The group said it was confident of putting together a consortium of banks to
finance the $43.7 billion buy of all outstanding shares in its U.S. partner and
that it sees no problems financing the deal.
(Reporting by Sam Cage) ($1=1.020 Swiss Franc) Keywords: ROCHE/GENENTECH
tf.TFN-Europe_newsdesk@thomsonreuters.com
jlw
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|